Copper and Zinc Levels in Myelodysplastic Syndrome Patients versus Healthy Subjects.
CONCLUSION: Overall, it can be concluded that because only a small proportion of the MDS patients enrolled in this study were found to have lower copper levels compared with the MDS patients population, further studies with a larger sample size and also clinical trials in MDS patients with serum zinc, and copper deficiency are recommended, and post-treatment hematological reassessment would also be beneficial to achieving more definitive results.
PMID: 31983190 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
More News: Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | Clinical Trials | Copper | Hematology | Iran Health | Iron | Laboratory Medicine | Middle East Health | Myelodysplastic Syndrome | Papanicolaou (Pap) Smear | Study | Zinc